Recent studies have focused on the convergence of glucagon-like peptide-1|GIP|glucagon receptor agonist therapies and dopamine communication. While GIP agonists are increasingly employed for managing type 2 diabetes mellitus, their potential effects on reward circuits, specifically governed by DA